Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Keld Kjeldsen*, Henning Bundgaard

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstract

    The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

    OriginalsprogEngelsk
    Sider (fra-til)702-707
    Antal sider6
    TidsskriftAnnals of the New York Academy of Sciences
    Vol/bind986
    DOI
    StatusUdgivet - 1 jan. 2003

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Myocardial Na,K-ATPase and digoxin therapy in human heart failure' indeholder.

    Citationsformater